We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Sincalide is an octapeptide fragment of cholestocystokinin (CCK) that activates the CCK receptor on immune cell surfaces. Sincalide is more potent when sulfated. Sincalide exhibits neuroprotective, immunosuppressive, and anorexigenic activities.
CAT No: R1676
CAS No: 25126-32-3
Synonyms/Alias: Sincalide;25126-32-3;CCK-8;Sincalida;Kinevac;Sincalidum;Syncalide;CCK C-terminal octapeptide;SQ 19844;Human CCK-8;cholecystokinin C-terminal octapeptide;Cholecystokinin octapeptide;UNII-M03GIQ7Z6P;3-10-Caerulein, 5-L-methionine-;M03GIQ7Z6P;DTXSID7048617;SQ-19844;Sincalidum [INN-Latin];EINECS 246-639-0;Sincalida [INN-Spanish];MFCD00079849;Cholecystokinin-pancreozymin;H-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2;Caerulein, 1-de(5-oxo-L-proline)-2-de-L-glutamine-5-L-methionine-;CHEMBL1121;DTXCID4028543;Sincalide [USAN:USP:INN:BAN];L-Aspartyl-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide hydrogen sulfate (ester);Sincalidum (INN-Latin);1-De(5-oxo-L-proline)-2-de-L-glutamine-5-L-methioninecaerulein;Sincalida (INN-Spanish);SINCALIDE (MART.);SINCALIDE [MART.];cholecystokinin 8;L-alpha-Aspartyl-O-sulfo-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamide;SINCALIDE (USP IMPURITY);SINCALIDE [USP IMPURITY];Sincalide (USAN:USP:INN:BAN);(3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid;(3S,6S,9S,15S,18S,21S)-9-((1H-indol-3-yl)methyl)-21-amino-3-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)carbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosanedioic acid;CAS-25126-32-3;CCK-8 (sulphated);CCK-OP;OP-CCK;CCK-8S;NCGC00183278-01;NCGC00183363-01;Kinevac (TN);SINCALIDE [INN];SINCALIDE [MI];CCK Octapeptide sulfated;Sincalide (USAN/INN);SINCALIDE [USAN];SINCALIDE [VANDF];SINCALIDE [WHO-DD];GTPL864;Cholecystokinin Pancreozymin C Terminal Octapeptide;Cholecystokinin Pancreozymin C-Terminal Octapeptide;SCHEMBL122365;CCK-8(SO3);SINCALIDE [ORANGE BOOK];BDBM21147;EX-A8006C;V04CC03;CHEBI:135946;Pancreozymin C-terminal octapeptide;[125I]CCK-8;HY-P0093;Tox21_112955;Tox21_113481;AKOS016340423;CS-5963;DB09142;FS41124;HS-2026;NCGC00167273-01;Cholecystokinin, CCK Octapeptide (26-33);NS00050642;D05845;E78048;Asp26-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-PheNH2;CHOLECYSTOKININ C-TERMINAL OCTAPEPTIDE [MI];EN300-19650945;Q7521885;(3S)-3-[(2S)-2-[(2S)-2-{2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-3-[4-(sulfooxy)phenyl]propanamido]-4-(methylsulfanyl)butanamido]acetamido}-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid;(3S)-3-[(2S)-2-[(2S)-2-{2-[(2S)-2-[(2S)-2-[(3S)-3-amino-3-formamidopropanoic acid]-3-[4-(sulfooxy)phenyl]propanamido]-4-(methylsulfanyl)butanamido]acetamido}-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid;(3S)-3-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-hydroxy-4-oxobutanoyl]amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid;(3S,6S,9S,15S,18S,21S)-9-((1H-indol-3-yl)methyl)-21-amino-3-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)carbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosane-1,23-dioic acid;(3S,6S,9S,15S,18S,21S)-9-((1H-indol-3-yl)methyl)-21-amino-3-((S)-1-amino-1-oxo-3-phenylpropan-2-ylcarbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosane-1,23-dioic acid;246-639-0;L-.ALPHA.-ASPARTYL-O-SULFO-L-TYROSYL-L-METHIONYLGLYCYL-L-TRYPTOPHYL-L-METHIONYL-L-.ALPHA.-ASPARTYL-L-PHENYLALANINAMIDE;L-Aspartyl-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide Hydrogen Sulfate(ester);
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C49H62N10O16S3 |
M.W/Mr. | 1143.3 |
Sequence | One Letter Code:DXMGWMDF Three Letter Code:H-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 |
Biological Activity | Sincalide (Cholecystokinin octapeptide) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is an agent that promotes gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. The hepatobiliary physiologic effect of Sincalide ammonium is to increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. |
Shipping Condition | Room temperature in continental US; may vary elsewhere. |
InChI | InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1 |
InChI Key | IZTQOLKUZKXIRV-YRVFCXMDSA-N |
2. Cationic cell-penetrating peptides are potent furin inhibitors
4. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com